originally published Friday, November 10, 2017

Printable Version

All Marijuana stocks

Although the large number of shares in issue is a drag factor for this stock, sometimes it is justified by the scale of a company’s operations, and while it is not known for sure if this is the case here, what is clear on the charts is that this stock is getting ready to break out upside to appreciate sufficiently over the medium-term to justify tasking a position in it here. We first looked at Liberty about a month ago when it was at C$1.11 and the technical condition of the stock has since continued to strengthen.

On its 1-year chart we can see that after starting trading again in July, Liberty drifted lower before recovering and then tracking sideways / up within a narrowing range beneath a resistance level at about C$1.20 – C$1.25, with moving averages swinging into bullish alignment. All the while upside volume has been building, driving volume indicators steeply higher, so that technically the situation is like a pressure cooker – this thing is going to blow in a positive way, with a breakout to the upside that should result in good percentage gains in fairly short order, despite the high number of shares in issue.

Liberty Health Sciences is accordingly rated an immediate strong buy, and anyone holding should of course stay long. Stops at personal discretion as there is a broad range of support beneath the current price. Liberty trades in good volumes on the US OTC market, where, as ever, limit orders should be employed.

Liberty Health Sciences website

Liberty Health Sciences, LHS.CSX, LHSIF on OTC, closed at C$1.19, $0.93 on 9th November 17.

The above represents the opinion and analysis of Mr Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stockmarket analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.